GlassScriptPhysician profile
Mary M Dobson
NPI 1952392318
$6,046.09
in general payments reported to CMS, 2019-2025
34 companies · $1,375 in 2025
The $1,375 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $532 · 2020: $307 · 2021: $550 · 2022: $1,147 · 2023: $1,209 · 2024: $928 · 2025: $1,375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,510.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,497.43 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Genzyme Corporation | $1,132.34 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $660.64 | 2019-2025 | |
| Janssen Biotech, INC. | $449.93 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Pfizer INC. | $363.43 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $314.38 | 2022-2025 | Sotyktu |
| Amgen INC. | $283.76 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $185.16 | 2019-2025 | Ebglyss, Olumiant, Taltz |
| Ucb, INC. | $142.29 | 2019-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $124.02 | 2019-2025 | Aklief, Oracea, Epsolay |
| Leo Pharma INC. | $87.72 | 2020-2025 | Anzupgo, Adbry |
| Medimetriks Pharmaceuticals, INC. | $75.04 | 2020 | |
| Biofrontera INC. | $63.30 | 2022-2025 | Xepi, Bf-Rhodoled, Rhodoled Xl |
| Genentech USA, INC. | $61.99 | 2019-2022 | |
| Allergan, INC. | $59.04 | 2020-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $58.06 | 2024-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $53.57 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $50.45 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $47.40 | 2019-2024 | Dupixent |
| Almirall LLC | $38.82 | 2019-2021 | |
| Incyte Corporation | $37.59 | 2023 | Opzelura |
| Elekta, INC. | $33.79 | 2025 | Flexitron Hdr |
| Mimedx Group, INC. | $29.02 | 2024 | |
| Kerecis Limited | $24.77 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.48 | 2025 | Spevigo |
| Conmed Corporation | $20.25 | 2025 | Visiclear |
| Merz North America, INC. | $19.80 | 2022 | |
| Smith+Nephew, INC. | $17.63 | 2020 | |
| Mayne Pharma Commercial LLC | $15.96 | 2019 | |
| Cipher Pharmaceuticals US LLC | $15.80 | 2025 | Spinosad, Natroba |
| Vyne Pharmaceuticals INC. | $15.53 | 2020 | |
| Dermavant Sciences, INC. | $14.83 | 2024 | Vtama |
| Celgene Corporation | $14.58 | 2019 | |
| Botanix Sb INC | $14.29 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Dobson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.